These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21971009)

  • 1. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
    Yogev-Falach M; Bar-Am O; Amit T; Weinreb O; Youdim MB
    FASEB J; 2006 Oct; 20(12):2177-9. PubMed ID: 16935943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
    Bar-Am O; Weinreb O; Amit T; Youdim MB
    J Mol Neurosci; 2009 Feb; 37(2):135-45. PubMed ID: 18751929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The neuroprotective mechanism of action of the multimodal drug ladostigil.
    Weinreb O; Amit T; Bar-Am O; Yogev-Falach M; Youdim MB
    Front Biosci; 2008 May; 13():5131-7. PubMed ID: 18508575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
    Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
    Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
    J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
    Weinstock M; Gorodetsky E; Poltyrev T; Gross A; Sagi Y; Youdim M
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):555-61. PubMed ID: 12787840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.
    Weinreb O; Bar-Am O; Amit T; Drigues N; Sagi Y; Youdim MB
    Chem Biol Interact; 2008 Sep; 175(1-3):318-26. PubMed ID: 18598687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
    Weinreb O; Mandel S; Bar-Am O; Yogev-Falach M; Avramovich-Tirosh Y; Amit T; Youdim MB
    Neurotherapeutics; 2009 Jan; 6(1):163-74. PubMed ID: 19110207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
    Youdim MB; Weinstock M
    Mech Ageing Dev; 2002 Apr; 123(8):1081-6. PubMed ID: 12044957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
    Weinstock M; Bejar C; Wang RH; Poltyrev T; Gross A; Finberg JP; Youdim MB
    J Neural Transm Suppl; 2000; (60):157-69. PubMed ID: 11205137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
    Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
    J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.
    Maruyama W; Weinstock M; Youdim MB; Nagai M; Naoi M
    Neurosci Lett; 2003 May; 341(3):233-6. PubMed ID: 12697291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
    Youdim MB; Weinstock M
    Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
    Weinstock M; Poltyrev T; Bejar C; Youdim MB
    Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
    Bolea I; Juárez-Jiménez J; de Los Ríos C; Chioua M; Pouplana R; Luque FJ; Unzeta M; Marco-Contelles J; Samadi A
    J Med Chem; 2011 Dec; 54(24):8251-70. PubMed ID: 22023459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
    Bautista-Aguilera OM; Esteban G; Bolea I; Nikolic K; Agbaba D; Moraleda I; Iriepa I; Samadi A; Soriano E; Unzeta M; Marco-Contelles J
    Eur J Med Chem; 2014 Mar; 75():82-95. PubMed ID: 24530494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.